TARRYTOWN, N.Y., July 7, 2021 /PRNewswire/ -- Regeneron
Pharmaceuticals, Inc. (NASDAQ: REGN) today
announced that it will report its second quarter 2021 financial and
operating results on Thursday, August 5,
2021, before the U.S. financial markets open. The
Company will host a conference call and simultaneous webcast at
8:30 AM Eastern Time that day.
Conference Call Information
To access this call, dial
(888) 660-6127 (U.S.) or (973) 890-8355 (International), conference
ID 9098036. A link to the webcast may be accessed from the
'Investors and Media' page of Regeneron's website at
replay of the conference call and webcast will be archived on the
Company's website for at least 30 days.
REGN) is a leading biotechnology company that invents
life-transforming medicines for people with serious diseases.
Founded and led for over 30 years by physician-scientists, our
unique ability to repeatedly and consistently translate science
into medicine has led to nine FDA-approved treatments and numerous
product candidates in development, almost all of which were
homegrown in our laboratories. Our medicines and pipeline are
designed to help patients with eye diseases, allergic and
inflammatory diseases, cancer, cardiovascular and metabolic
diseases, pain, infectious diseases and rare diseases.
Regeneron is accelerating and improving the traditional drug
development process through our
proprietary VelociSuite® technologies,
such as VelocImmune®, which uses unique
genetically humanized mice to produce optimized fully human
antibodies and bispecific antibodies, and through ambitious
research initiatives such as the Regeneron Genetics Center, which
is conducting one of the largest genetics sequencing efforts in the
For additional information about the company, please
visit www.regeneron.com or follow @Regeneron on
SOURCE Regeneron Pharmaceuticals, Inc.